New York, NY – April 28, 2026 – Ambio Pharm Inc. announced today that its investigational peptide SCAM-47 (Synthetic Colloidally Aggregating Motif-47) has successfully completed Phase I clinical evaluation, with …
Copyright © CB Herald. 2026
